Fecal calprotectin and ulcerative colitis endoscopic activity index as indicators of mucosal healing in ulcerative colitis

Internal and Emergency Medicine

Volumn 10, Issue 3, 2015, Pages 321-328

  Taghvaei, Tarang ^a   Maleki, Iradj ^a   Nagshvar, Farshad ^b   Fakheri, Hafez ^a   Hosseini, Vahid ^a   Valizadeh, Seyed Mohammad ^a   Neishaboori, Hassan ^a  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Calprotectin; Inflammatory bowel disease; Mucosal healing; UCEIS; Ulcerative colitis

Indexed keywords

BIOLOGICAL MARKER; CALGRANULIN;

ADULT; CHEMISTRY; FECES; FEMALE; GASTROINTESTINAL ENDOSCOPY; HUMAN; INTESTINE MUCOSA; MALE; PATHOLOGY; PROGNOSIS; SEVERITY OF ILLNESS INDEX; ULCERATIVE COLITIS;

ADULT; BIOMARKERS; COLITIS, ULCERATIVE; ENDOSCOPY, GASTROINTESTINAL; FECES; FEMALE; HUMANS; INTESTINAL MUCOSA; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 84939996677     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-014-1144-x     Document Type: Article

References (33)

1. Langhorst J, Elsenbruch S, Mueller T et al (2005) Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis 11(12):1085–1091
2. Fefferman DS, Farrell RJ (2005) Endoscopy in inflammatory bowel disease: indications, surveillance, and use in clinical practice. Clin Gastroenterol Hepatol: the official clinical practice journal of the American Gastroenterological Association. 3(1):11–24
3. Schoepfer AM, Beglinger C, Straumann A et al (2009) Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 15(12):1851–1858
4. Angriman I, Scarpa M, D’Inca R et al (2007) Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin Chim Acta; International Journal Of Clinical Chemistry. 381(1):63–68
5. Travis SP, Schnell D, Krzeski P et al (2013) Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology 145(5):987–995
6. Walsh AJ, Ghosh A, Brain AO et al (2014) Comparing disease activity indices in ulcerative colitis. J Crohns Colitis 8(4):318–325
7. Carpenter HA, Talley NJ (2000) The importance of clinicopathological correlation in the diagnosis of inflammatory conditions of the colon: histological patterns with clinical implications. Am J Gastroenterol 95(4):878–896
8. Nikolaus S, Schreiber S (2007) Diagnostics of inflammatory bowel disease. Gastroenterology 133(5):1670–1689
9. Vermeire S, Van Assche G, Rutgeerts P (2006) Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 55(3):426–431
10. Desai D, Faubion WA, Sandborn WJ (2007) Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther 25(3):247–255
11. Gisbert JP, Gonzalez-Lama Y, Mate J (2007) Role of biological markers in inflammatory bowel disease. Gastroenterol Hepatol 30(3):117–129
12. Tibble JA, Sigthorsson G, Bridger S et al (2000) Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 119(1):15–22
13. Tibble JA, Bjarnason I (2001) Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol 7(4):460–465
14. Bitton A, Peppercorn MA, Antonioli DA et al (2001) Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 120(1):13–20
15. Sutherland AD, Gearry RB, Frizelle FA (2008) Review of fecal biomarkers in inflammatory bowel disease. Dis Colon Rectum 51(8):1283–1291
16. Geboes K, Riddell R, Ost A et al (2000) A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 47(3):404–409
17. Bjerke K, Halstensen TS, Jahnsen F et al (1993) Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human Peyer’s patches compared with normal ileal lamina propria and mesenteric lymph nodes. Gut 34(10):1357–1363
18. Costa F, Mumolo MG, Ceccarelli L et al (2005) Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut 54(3):364–368
19. Johne B, Fagerhol MK, Lyberg T et al (1997) Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol 50(3):113–123
20. Konikoff MR, Denson LA (2006) Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 12(6):524–534
21. Xiang JY, Ouyang Q, Li GD et al (2008) Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J Gastroenterol 14(1):53–57
22. Langhorst J, Elsenbruch S, Koelzer J et al (2008) Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 103(1):162–169
23. Canani RB, Terrin G, Rapacciuolo L et al (2008) Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 40(7):547–553
24. Silberer H, Kuppers B, Mickisch O et al (2005) Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab 51(3–4):117–126
25. Gisbert JP, McNicholl AG (2009) Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 41(1):56–66
26. Garcia-Sanchez V, Iglesias-Flores E, Gonzalez R et al (2010) Does fecal calprotectin predict relapse in patients with Crohn’s disease and ulcerative colitis? J Crohns Colitis 4(2):144–152
27. D’Haens G, Sandborn WJ, Feagan BG et al (2007) A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 132(2):763–786
28. Naganuma M, Ichikawa H, Inoue N et al (2010) Novel endoscopic activity index is useful for choosing treatment in severe active ulcerative colitis patients. J Gastroenterol 45(9):936–943
29. Travis SP, Schnell D, Krzeski P et al (2012) Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 61(4):535–542
30. Rachmilewitz D (1989) Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 298(6666):82–86
31. Cooney RM, Warren BF, Altman DG et al (2007) Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation. Trials 8:17
32. Gisbert JP, Bermejo F, Perez-Calle JL et al (2009) Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 15(8):1190–1198
33. Kaiser T, Langhorst J, Wittkowski H et al (2007) Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 56(12):1706–1713